^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance

Published date:
04/12/2023
Excerpt:
...we investigated the efficacy of two novel CDK12/13 inhibitors, AU-15506 and AU-16770, in osimertinib-resistant EGFR mutant lung adenocarcinoma cells in culture and xenograft models in vivo...only the CDK12/13 inhibitor in combination with osimertinib, although not as monotherapy, suppresses the growth of resistant tumors in xenograft models in vivo...when AU-15506 was administered in combination with osimertinib, significant tumor shrinkage was observed within 14 days (Supplementary Figure S3A–C).
DOI:
https://doi.org/10.3390/cancers15082263